3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Other solid neoplasm
2
Conditions
Carcinoma, Non-Small-Cell Lung
21
Lung Neoplasms
7
Breast Neoplasms
4
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Neoplasms
2
Multiple Myeloma
2
Mesothelioma
2
Esophageal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Ovarian Epithelial
2
Brain Neoplasms
2
Stomach Neoplasms
1
Stage IIIB or IV Non-Small Cell Lung Cancer
1
Sezary Syndrome
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Mycosis Fungoides
1
Mesothelioma, Malignant
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Interventions
Pemetrexed
40
Cisplatin
35
pembrolizumab
21
Nivolumab
17
Carboplatin
16
Ipilimumab
13
Gemcitabine
10
Cyclophosphamide
9
fludarabine
6
durvalumab
6
Bevacizumab
6
Radiotherapy, Intensity-Modulated
4
LMB-100
4
Drug Therapy
4
Dexamethasone
4
tremelimumab
3
tazemetostat
3
spartalizumab
3
olaparib
3
niraparib
3
atezolizumab
3
anetumab ravtansine
3
amatuximab
3
Vinorelbine
3
Paclitaxel
3
Oxaliplatin
3
Imatinib Mesylate
3
Fluorouracil
3
Cerebral Decortication
3
Blood Specimen Collection
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Mesothelioma
×
Vorinostat
×
Thoracic
×
Clear all
NCT00128102
2020-10-26
MK-0683-014
Merck Sharp & Dohme LLC
Phase 3
Completed
661 enrolled
18 charts
NCT01353482
2012-03-22
MESO-02
University College, London
Phase 1/2
Withdrawn